Infinity Pharmaceuticals Inc (INFI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description - A detailed description of the company's operations and business divisions.
- Corporate strategy - Analyst's summarization of the company's business strategy.
- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Infinity Pharmaceuticals Inc (Infinity Pharmaceuticals) is a biopharmaceutical company which discovers and develops small molecule therapeutics for the treatment of cancer. The company's pipeline candidate: IPI-549 selectively inhibits PI3K-gamma to reprogram tumor-associated macrophages and transforms immuno-oncology approach. The company is evaluating IPI-549 as a monotherapy and in a combination therapy in various clinical trials for the treatment of various indications such advanced solid tumors, non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple negative breast cancer (TNBC), mesothelioma and myeloid-derived suppressor cells (MDSC). The company has collaborations with other biopharmaceuticals companies for the development of its pipeline programs. Infinity Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.Infinity Pharmaceuticals Inc Key Recent Developments
- Nov 14, 2022: Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
- Aug 09, 2022: Infinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
- Aug 02, 2022: Infinity Pharmaceuticals Announces the Date of Its Second Quarter 2022 Financial Results Conference Call and Webcast
- May 03, 2022: Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Vaccinex Inc
- Takeda Pharmaceuticals International Inc
- Syntrix Pharmaceuticals
- Syndax Pharmaceuticals Inc
- Incyte Corp
- Janssen Research & Development LLC
- Deciphera Pharmaceuticals Inc
- Surface Oncology Inc
- Eisai Co Ltd
- Apexigen Inc
- Trillium Therapeutics Inc
- Seagen Inc
- Plexxikon Inc
- Array BioPharma Inc
- XBiotech Inc
- X4 Pharmaceuticals Inc
- Syndax Pharmaceuticals Inc
- Janssen Research & Development LLC
- Vaccinex Inc
- AbbVie Inc
- Takeda Pharmaceuticals International Inc
- Novartis AG
- Trillium Therapeutics Inc
- Surface Oncology Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Alligator Bioscience AB
- F. Hoffmann-La Roche Ltd
- Deciphera Pharmaceuticals Inc
- Amgen Inc
- Incyte Corp
- Seagen Inc
- Plexxikon Inc
- GlaxoSmithKline Inc
- Celgene Corp
- AstraZeneca Plc
- Syntrix Pharmaceuticals
- Apexigen Inc